Page last updated: 2024-09-03

n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine and batimastat

n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine has been researched along with batimastat in 1 studies

Compound Research Comparison

Studies
(n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine)
Trials
(n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine)
Recent Studies (post-2010)
(n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine)
Studies
(batimastat)
Trials
(batimastat)
Recent Studies (post-2010) (batimastat)
79116347656

Protein Interaction Comparison

ProteinTaxonomyn-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine (IC50)batimastat (IC50)
5-hydroxytryptamine receptor 3EHomo sapiens (human)0.025
5-hydroxytryptamine receptor 3BHomo sapiens (human)0.025
Interstitial collagenaseHomo sapiens (human)0.3158
Low affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)0.1
72 kDa type IV collagenaseHomo sapiens (human)0.3029
Stromelysin-1Homo sapiens (human)1.1205
MatrilysinHomo sapiens (human)3.5012
Matrix metalloproteinase-9Homo sapiens (human)0.0066
Neutrophil collagenaseHomo sapiens (human)0.7
Metabotropic glutamate receptor 5Rattus norvegicus (Norway rat)1.2
Collagenase 3Homo sapiens (human)0.005
5-hydroxytryptamine receptor 3AHomo sapiens (human)0.025
Matrix metalloproteinase-14Homo sapiens (human)0.5715
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)0.0149
Snake venom metalloproteinase BaP1Bothrops asper (terciopelo)1.2
5-hydroxytryptamine receptor 3DHomo sapiens (human)0.025
5-hydroxytryptamine receptor 3CHomo sapiens (human)0.025

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1

Other Studies

1 other study(ies) available for n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine and batimastat

ArticleYear
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023